Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 28/10/2020
SIETES contiene 93136 citas

 1 a 20 de 27 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Moynihan R, Albarqouni L, Nangla C, Dunn AG+, Lexchin J, Bero L. Financial ties between leaders of influential US professional medical associations and industry: cross sectional study. BMJ 2020;369:27 de mayo. [Ref.ID 103650]
2. Cita con resumen
Habibi R, Lexchin J, Mintzes B, Holbrook A. Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?. Br J Clin Pharmacol 2017;83:2549-56. [Ref.ID 102116]
3.Tiene citas relacionadas Cita con resumen
Davis C, Lexchin J, Jefferson T, Gotzsche P, McKee M. "Adaptive pathways” to drug authorisation: adapting to industry?. BMJ 2016;354:i4437. [Ref.ID 100602]
4. Cita con resumen
Light DW, Lexchin J. Why do cancer drugs get such an easy ride?. BMJ 2015;350:h2068. [Ref.ID 98977]
5. Cita con resumen
Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med 2013;173:611-2. [Ref.ID 95286]
6. Cita con resumen
Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med 2013;28:1368-75. [Ref.ID 95199]
7. Cita con resumen
Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ 2012;345:18. [Ref.ID 94316]
9.Tiene citas relacionadas Cita con resumen
Light D, Lexchin J. Pharmaceutical R&D. What do we get for all that money?. BMJ 2012;345:22-5. [Ref.ID 93566]
10. Cita con resumen
Braillon A, Bewley S, Herxheimer A, Mansfield P, Lexchin J, Menkes DB, Ziganshina LE, Montastruc J-L. Marketing versus evidence-based medicine. Lancet 2012;380:340. [Ref.ID 93515]
11. Cita con resumen
Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 2011;305:1008-17. [Ref.ID 90287]
12.Enlace a cita original Cita con resumen
Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI. Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLOS Medicine 2010;7:352. [Ref.ID 89239]
13.Enlace a cita original Cita con resumen
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLOS Medicine 2007;4:1. [Ref.ID 81039]
15. Cita con resumen
Lexchin J, Light DW. Commercial influence and the content of medical journals. BMJ 2006;332:1444-7. [Ref.ID 77284]
16.Enlace a cita original Cita con resumen
Lexchin J. Bigger and better: how Pfizer redefined erectile dysfunction. PLOS Medicine 2006;3:132. [Ref.ID 77179]
17. Cita con resumen
Lexchin J. Withdrawals of drugs for safety reasons: how do regulators decide if they are too unsafe?. Adv Drug React Bull 2006;236:903-6. [Ref.ID 76689]
18. Cita con resumen
Lexchin J. Clinical trials register. Lancet 2004;364:330. [Ref.ID 70911]
19. Cita con resumen
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70. [Ref.ID 66395]
20. Cita con resumen
Henry D, Lexchin J. Patent law. Lancet 2003;361:1059. [Ref.ID 65482]
Seleccionar todas
 1 a 20 de 27 siguiente >>